Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
233.50
+4.51 (1.97%)
At close: Feb 27, 2026, 4:00 PM EST
243.00
+9.50 (4.07%)
After-hours: Feb 27, 2026, 7:55 PM EST
Ascendis Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 720.13 | 363.64 | 266.72 | 51.17 | 7.78 | Upgrade
|
| Revenue Growth (YoY) | 98.03% | 36.34% | 421.20% | 557.93% | 11.87% | Upgrade
|
| Cost of Revenue | 94.92 | 44.26 | 44.4 | 12.14 | 3.52 | Upgrade
|
| Gross Profit | 625.22 | 319.38 | 222.32 | 39.04 | 4.26 | Upgrade
|
| Selling, General & Admin | 457.87 | 291.14 | 264.41 | 221.23 | 160.18 | Upgrade
|
| Research & Development | 303.62 | 307 | 413.45 | 379.62 | 295.87 | Upgrade
|
| Operating Expenses | 761.49 | 598.15 | 677.86 | 600.85 | 456.05 | Upgrade
|
| Operating Income | -136.27 | -278.76 | -455.54 | -561.81 | -451.79 | Upgrade
|
| Interest Expense | -80.65 | -65.5 | -44.07 | -30.68 | -3.91 | Upgrade
|
| Interest & Investment Income | 15.3 | 14.36 | 16.86 | 7.43 | 0.69 | Upgrade
|
| Earnings From Equity Investments | 16.31 | -20.06 | -18.4 | -17.7 | 12.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 78.23 | -27.15 | 12.35 | 40.43 | 59.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -105.57 | 3.87 | 14.65 | -15.48 | - | Upgrade
|
| Pretax Income | -212.65 | -373.24 | -474.14 | -577.82 | -383.94 | Upgrade
|
| Income Tax Expense | 15.38 | 4.84 | 7.3 | 5.38 | -0.37 | Upgrade
|
| Net Income | -228.03 | -378.08 | -481.45 | -583.19 | -383.58 | Upgrade
|
| Net Income to Common | -228.03 | -378.08 | -481.45 | -583.19 | -383.58 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 58 | 56 | 56 | 55 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 58 | 56 | 56 | 55 | Upgrade
|
| Shares Change (YoY) | 4.69% | 2.85% | 0.38% | 2.37% | 8.21% | Upgrade
|
| EPS (Basic) | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 | Upgrade
|
| EPS (Diluted) | -3.76 | -6.53 | -8.55 | -10.40 | -7.00 | Upgrade
|
| Free Cash Flow | 45.41 | -307.62 | -469.8 | -510.19 | -441.35 | Upgrade
|
| Free Cash Flow Per Share | 0.75 | -5.31 | -8.35 | -9.10 | -8.06 | Upgrade
|
| Gross Margin | 86.82% | 87.83% | 83.36% | 76.28% | 54.71% | Upgrade
|
| Operating Margin | -18.92% | -76.66% | -170.80% | -1097.85% | -5808.59% | Upgrade
|
| Profit Margin | -31.67% | -103.97% | -180.51% | -1139.63% | -4931.56% | Upgrade
|
| Free Cash Flow Margin | 6.31% | -84.60% | -176.14% | -996.97% | -5674.38% | Upgrade
|
| EBITDA | -131.42 | -273.83 | -437.11 | -544.3 | -436.85 | Upgrade
|
| EBITDA Margin | -18.25% | -75.30% | -163.89% | - | - | Upgrade
|
| D&A For EBITDA | 4.86 | 4.94 | 18.43 | 17.51 | 14.95 | Upgrade
|
| EBIT | -136.27 | -278.76 | -455.54 | -561.81 | -451.79 | Upgrade
|
| EBIT Margin | -18.92% | -76.66% | -170.80% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.